NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $28.24 +1.30 (+4.83%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$26.72▼$28.1450-Day Range$16.80▼$28.9652-Week Range$16.24▼$45.30Volume987,021 shsAverage Volume2.35 million shsMarket Capitalization$5.22 billionP/E RatioN/ADividend YieldN/APrice Target$59.00Consensus RatingModerate Buy Company Overview Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma. Carvykti received U.S. Food and Drug Administration approval in February 2022, marking Legend Biotech’s transition into commercial operations. Beyond its flagship program, the company maintains a diversified pipeline, which includes additional hematologic and solid-tumor cell therapy candidates and next-generation platform technologies designed to enhance safety, scalability and patient access. Founded in 2014 and backed by a robust collaboration agreement with Janssen, Legend Biotech completed its initial public offering on the Nasdaq in July 2019. The capital raise supported expansion of manufacturing capacity and accelerated global clinical development. Through its relationship with Janssen, Legend Biotech has laid the groundwork for regulatory filings and product launches across North America, Europe and Asia, leveraging Janssen’s established commercial network. The company is led by Chief Executive Officer Dr. Ying Huang, whose leadership team combines expertise in cell therapy research, regulatory affairs and commercial execution. As Legend Biotech advances its clinical programs and scales its commercial infrastructure, it remains focused on expanding patient access to transformative therapies and exploring new indications in oncology.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreLEGN MarketRank™: Legend Biotech scored higher than 80% of companies evaluated by MarketBeat, and ranked 166th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 11 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $59.00, representing about 113.6% upside from its current price of $27.62.Amount of Analyst CoverageLegend Biotech has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth740.00% Earnings GrowthEarnings for Legend Biotech are expected to grow by 740.00% in the coming year, from $0.20 to $1.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -40.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -40.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.19% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 6.24.Change versus previous monthShort interest in Legend Biotech has recently decreased by 11.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.07 News SentimentLegend Biotech has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $87,139.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)May 19 at 10:20 AM | theglobeandmail.comA China Tech Fund Opens a Biotech Position — Here's What That Actually SignalsMay 17 at 5:01 PM | fool.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 20 at 1:00 AM | Behind the Markets (Ad)Legend Biotech Corporation 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comLegend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing LossesMay 15, 2026 | finance.yahoo.comBarclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ovid Therapeutics (OVID) and Arvinas Holding Company (ARVN)May 14, 2026 | theglobeandmail.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 on January 1st, 2026. Since then, LEGN shares have increased by 27.1% and is now trading at $27.6240. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. Legend Biotech's quarterly revenue was up 56.5% compared to the same quarter last year. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,425,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional investors include Matthews International Capital Management LLC (0.50%), SG Americas Securities LLC (0.29%), Renaissance Technologies LLC (0.28%) and Candriam S.C.A. (0.25%). View institutional ownership trends. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 4 weeks, LEGN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$59.00 High Price Target$80.00 Low Price Target$24.00 Potential Upside/Downside+113.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E Ratio138.12 P/E GrowthN/ANet Income-$296.80 million Net Margins-21.98% Pretax Margin-20.77% Return on Equity-24.92% Return on Assets-14.87% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio2.05 Sales & Book Value Annual Sales$1.03 billion Price / Sales4.97 Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book5.28Miscellaneous Outstanding Shares184,960,000Free Float184,919,000Market Cap$5.11 billion OptionableOptionable Beta0.29 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LEGN) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.Bitcoin continues struggling. Traders are pulling back. And most retail investors are sitting frozen waiting f...Crypto 101 Media | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored"Nobody will remember Tesla cars…"Elon Musk himself said it plainly: 'We should be thought of as an AI robotics company.' One famous angel inves...The Oxford Club | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
